The
COVID-19
pandemic
has
caused
a
global
health
crisis
and
significant
social
economic
burden.
While
most
individuals
experience
mild
or
non-specific
symptoms,
elderly
are
at
higher
risk
of
developing
severe
symptoms
life-threatening
complications.
Exploring
the
key
factors
associated
with
clinical
severity
highlights
that
characteristics
aging,
such
as
cellular
senescence,
immune
dysregulation,
metabolic
alterations,
impaired
regenerative
potential,
contribute
to
disruption
tissue
homeostasis
lung
worse
outcome.
Senolytic
senomorphic
drugs,
which
anti-aging
treatments
designed
eliminate
senescent
cells
decrease
phenotypes,
have
shown
promise
in
alleviating
age-related
dysfunctions
offer
novel
approach
treating
diseases
share
certain
aspects
underlying
mechanisms
including
COVID-19.
This
review
summarizes
current
understanding
aging
progression,
recent
findings
on
drugs
could
be
repurposed
for
treatment
complement
existing
therapies.
Pharmaceuticals,
Год журнала:
2024,
Номер
17(5), С. 597 - 597
Опубликована: Май 7, 2024
Inflammaging,
a
coexistence
of
inflammation
and
aging,
is
persistent,
systemic,
low-grade
seen
in
the
geriatric
population.
Various
natural
compounds
have
been
greatly
explored
for
their
potential
role
preventing
treating
inflammaging.
Withania
somnifera
has
used
thousands
years
traditional
medicine
as
nutraceutical
its
numerous
health
benefits
including
regenerative
adaptogenic
effects.
Recent
preclinical
clinical
studies
on
active
inflammation,
oxidative
stress
shown
promise
use
healthy
aging.
We
discuss
chemistry
somnifera,
etiology
inflammaging
protective
role(s)
key
organ
systems
brain,
lung,
kidney,
liver
well
mechanistic
underpinning
these
Furthermore,
we
elucidate
beneficial
effects
stress/DNA
damage,
immunomodulation,
COVID-19,
microbiome.
also
delineate
putative
protein–protein
interaction
network
biomarkers
modulated
by
In
addition,
review
safety/potential
toxicity
global
trials
somnifera.
Taken
together,
this
synthetic
highlights
improving
health-related
quality
life
(HRQoL)
aging
population
worldwide.
Regenerative Therapy,
Год журнала:
2024,
Номер
27, С. 319 - 328
Опубликована: Апрель 16, 2024
The
severe
respiratory
effects
of
the
coronavirus
disease
2019
(COVID-19)
pandemic
have
necessitated
immediate
development
novel
treatments.
majority
COVID-19-related
fatalities
are
due
to
acute
distress
syndrome
(ARDS).
Consequently,
this
virus
causes
massive
and
aberrant
inflammatory
conditions,
which
must
be
promptly
managed.
Severe
disorders,
notably
ARDS
lung
injury
(ALI),
may
treated
safely
effectively
using
cell-based
treatments,
mostly
employing
mesenchymal
stem
cells
(MSCs).
Since
high
potential
these
was
identified,
a
great
deal
research
has
been
conducted
on
their
use
in
regenerative
medicine
complementary
medicine.
Multiple
investigations
demonstrated
that
MSCs
products,
especially
exosomes,
inhibit
inflammation.
Exosomes
serve
critical
function
intercellular
communication
by
transporting
molecular
cargo
from
donor
receiver
cells.
derived
exosomes
(MSCs/MSC-exosomes)
improve
permeability,
microbial
alveolar
fluid
clearance,
epithelial
endothelial
repair,
according
recent
studies.
This
review
focuses
clinical
studies
involving
MSCs/MSC-exosomes.
We
also
investigated
utilization
Nano-delivery
strategies
for
MSCs/MSC-exosomes
anti-inflammatory
agents
enhance
COVID-19
treatment.
Annals of Medicine,
Год журнала:
2023,
Номер
55(2)
Опубликована: Окт. 15, 2023
Background:
COVID-19
continues
to
present
challenges
in
the
care
of
older
adults
with
frailty
and/or
comorbidities
and
very
old
patients,
who
can
be
hospitalized
severe
despite
full
vaccination.
Frailty
is
a
heterogeneous
syndrome
characterized
by
an
increased
aging-related
vulnerability
due
reduced
physiological
reserve
function
systemic
organs,
associated
impairment
activities
daily
living.
Frail
remain
at
elevated
risk
mortality
from
compared
without
frailty,
some
pre-existing
factors
such
as
malnutrition,
prolonged
bed
rest,
association
aggravate
SARS-CoV-2
infection.
Furthermore,
severity
impact
on
long-term
functioning
patients
surviving
Persistent
symptoms
are
another
emerging
problem
post-vaccination
phase
pandemic,
most
suffer
chronic
which
become
debilitating
affect
routine.
Aim
this
review:
In
complex
relationship,
evaluation
vulnerable
categories
still
matter
high
interest
personalized
plans
based
comprehensive
geriatric
assessment,
tailored
interventions;
specific
therapeutic
algorithms
among
thus
recommended
order
improve
outcomes.
Journal of Medical Virology,
Год журнала:
2023,
Номер
95(9)
Опубликована: Сен. 1, 2023
Abstract
In
China,
the
emergence
of
a
nationally
widespread
epidemic
infection
severe
acute
respiratory
syndrome
coronavirus
2
(SARS‐COV‐2)
has
appeared
within
month
since
December
7,
2022.
To
evaluate
risk
factors
for
suffering
from
disease
2019
(COVID‐19)
pneumonia
due
to
with
SARS‐CoV‐2
in
different
kinds
interstitial
lung
(ILD)
patients
diverse
immunizations,
we
conducted
this
retrospective
study
on
525
ILDs
who
underwent
regular
follow‐up
our
ILD
clinic.
Among
them,
128
(24.4%)
suffered
COVID‐19
after
infection.
Patients
were
older
male
predominance
group
than
nonpneumonia
(65.0
±
10.0
years
vs.
56.4
11.7
years,
p
<
0.001,
55.5%
39.5%,
=
0.002,
respectively).
Connective
tissue
disease‐associated
(CTD‐ILD)
(25%),
idiopathic
pulmonary
fibrosis
(23.4%),
and
autoimmune
features
(21.1%)
main
pre‐existing
group.
Cox
multivariable
analysis,
only
sex
corticosteroid
use
Two
or
three
doses
vaccination
protective
factor
pneumonia.
More
two
strongly
recommended
patients,
particularly
males
administered
corticosteroids.
Aging and Disease,
Год журнала:
2024,
Номер
unknown, С. 0 - 0
Опубликована: Янв. 1, 2024
Age-induced
alterations
in
human
immunity
are
often
considered
deleterious
and
referred
to
as
immunosenescence.
The
immune
system
monitors
the
number
of
senescent
cells
body,
while
immunosenescence
may
represent
initiation
systemic
aging.
Immune
cells,
particularly
T
most
impacted
involved
age-related
function
deterioration,
making
older
individuals
more
prone
different
diseases.
T-cell
senescence
can
impact
effectiveness
immunotherapies
that
rely
on
system's
function,
including
vaccines
adoptive
therapies.
research
practice
using
therapeutic
targets
intervene
diseases
their
nascent
stages.
Therefore,
this
review,
we
summarize
recent
related
literature
investigate
characteristics
well
formation
mechanisms,
relationship
with
various
aging-related
diseases,
means
intervention.
primary
objective
article
is
explore
prospects
possibilities
therapeutically
targeting
serving
a
valuable
resource
for
development
immunotherapy
treatment
Abstract
Background
Advancing
age
is
a
major
risk
factor
for
respiratory
viral
infections.
The
infections
are
often
prolonged
and
difficult
to
resolve
resulting
hospitalizations
mortality.
recent
COVID-19
pandemic
has
highlighted
this
as
elderly
subjects
have
emerged
vulnerable
populations
that
display
increased
susceptibility
severity
SARS-CoV-2.
There
an
urgent
need
identify
the
probable
mechanisms
underlying
protect
against
future
outbreaks
of
such
nature.
Innate
immunity
first
line
defense
viruses
its
decline
impacts
downstream
immune
responses.
This
because
dendritic
cells
(DCs)
macrophages
key
cellular
elements
innate
system
can
sense
respond
by
producing
inflammatory
mediators
priming
CD4
CD8
T-cell
Results
We
investigated
changes
in
responses
SARS-CoV-2
function
age.
Our
results
using
human
PBMCs
from
aged,
middle-aged,
young
indicate
activation
DCs
monocytes
response
compromised
with
impairment
most
apparent
pDCs
where
both
aged
middle-aged
reduced
secretion
IL-29
confers
protection
also
decreased
subjects.
In
contrast,
associated
severe
including
CXCL-8,
TREM-1
gene
expression
data
pathways
related
host
dependent
decrease
concomitant
increase
pathways.
Not
only
after
stimulation
but
at
homeostasis.
keeping
DC
activation,
induction
cytotoxic
T
impaired
However,
baseline
accordance
enhanced
inflammation.
Conclusions
demonstrate
protective
anti-viral
damaging
indicating
dysregulated
play
significant
role
COVID-19.
Furthermore,
dysregulation
develops
early
on
several
these
changes.
Graphical
abstract
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Апрель 24, 2025
Identifying
immune
markers
driving
early
and
effective
antibody
response
in
patients
with
severe
coronavirus
disease
2019
(COVID-19)
is
critical
due
to
the
threat
of
future
pandemics,
incomplete
global
vaccination,
suboptimal
booster
coverage.
Patients
life-threatening
acute
respiratory
syndrome
2
(SARS-CoV-2)
infection
are
characterized
by
dysregulated
thromboinflammation
cytokine
storm
that
could
influence
isotype
virus-specific
subsequent
clinical
outcome.
We
investigated
association
between
COVID-19-related
mortality
dynamics,
magnitude,
relative
avidity
nucleoprotein
(N),
spike
(S),
receptor-binding
domain
(RBD)-specific
IgM,
IgA,
IgG
circulation.
also
assessed
relationship
responses
patterns,
as
well
systemic
pulmonary
markers.
This
multicenter
study
included
COVID-19
hospitalized
pandemic,
classified
survivors
(n=62)
non-survivors
(n=17).
developed
indirect
enzyme-linked
immunosorbent
assays
(ELISAs)
evaluate
each
using
well-characterized
outpatient
(n=180)
pre-pandemic
cohorts
(n=111).
The
pro-inflammatory
interleukin
(IL)-6
tumor
necrosis
factor
(TNF)-α,
regulatory
IL-10,
transforming
growth
(TGF)-β1,
soluble
receptor
I
(sTNFRI)
levels
were
evaluated.
ELISAs
performed
highly
for
all
isotypes,
although
modest
IgM-N.
Non-survivors
increased
N-specific,
but
no
S-specific,
IgM
IgA
throughout
course
and,
more
notably,
a
delayed
class
switching
IgG-S
IgG-RBD
compared
survivors.
No
differences
observed
avidity.
Survivors
exhibited
an
proportional
degree
thromboinflammation,
whereas
showed
those
dissociated
because
their
uncontrolled
thromboinflammation.
Only
dominant
pattern
phase
(<10
days
after
symptoms
onset),
which
strongly
correlated
developing
protective
antibodies.
easy-to-use
enable
patient
monitoring
identify
at-risk
populations
low-
middle-income
regions.
displayed
ineffective
N-mediated
response,
marked
inability
control
inflammation
compromised
time-dependent
toward
S
RBD-specific
IgG.
axis,
including
TGF-β1,
maybe
correlate
antibody-mediated
immunity
COVID-19.